xRead - Nasal Obstruction (September 2024) Full Articles

20426984, 2021, 3, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/alr.22741 by Stanford University, Wiley Online Library on [01/07/2024]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License

295

Orlandi et al.

TABLE VII-10 Evidence for amoxicillin vs amoxicillin-clavulanate in ARS Study Year LOE Study Design Study Groups Clinical Endpoint Conclusions Garbutt 412 2001 2 RCT in pediatric patients Amoxicillin Amoxicillin + clavulanate Placebo Telephone interviews at 3 to60days Day 14 improvement rate was similar between groups. Similar relapse/ recurrence rates Wald 413 1986 2 RCT in pediatric patients Amoxicillin Amoxicillin + clavulanate Placebo Telephone questionnaire at 1 to 10 days Both antibiotics were superior to placebo at days 3 and 10 Anon 408 2006 3 Cohort study Amoxicillin-clavulanate Bacterial eradication or no clinical evidence of infection Success in 87.8% Brook 409 2005 3 Cohort study Amoxicillin + clavulanate with 2 different

Bacteria were isolated pre and post-therapy

greater in the latter time period

Pneumococcal prevalence low (2.6%); penicillin resistance high (64.3%)

resistance in 58% to 72% for common pathogens

Prevalence of MRSA was

First line penicillin class

Prevalence of S. aureus andMRSA

nasopharyngeal swab

pre- and post-therapy

Bacterial isolates and resistance

Prevalence of antibiotic resistance

Bacteria isolated by

different time periods

amoxicillin doses (4 gm/d v. 1.5 gm/d)

Olwoch 414 2010 4 Case series Patients with complicated RS treated with

antibiotics and surgery Culture data from 2

Huang 410 2004 4 Case series Middle meatal discharge cultured during ARS episode

Brook 415 2008 4 Retrospective series without control